- Home
- KYNB vs BYSI Comparison
KYNB vs BYSI Comparison
Compare KYNB & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | BYSI |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 31.4M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KYNB | BYSI |
|---|---|---|
| Price | $7.87 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.1K | ★ 112.1K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9552.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $0.57 |
| 52 Week High | $9.58 | $2.44 |
Technical Indicators
Market Signals| Indicator | KYNB | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 48.62 |
| Support Level | $7.40 | $0.58 |
| Resistance Level | $7.95 | $1.25 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 45.43 | 84.84 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.